Drug Topics

MAY 5, 2025

Casey Koch, PharmD, MBA, BCACP, clinical pharmacy coordinator at SelectHealth discusses how pharmacists can reduce patient burden.

415

415

PhRMA

MAY 5, 2025

PBM’s trade association, PCMA, recently launched a campaign to mask growing concerns over their role in the pharmaceutical supply chain and the rising cost of medicine for patients. The campaign is in response to elected officials nationwide joining the congressional momentum in calling for PBM reform. It’s time to rein in middlemen, like PBMs, who use medicines as a profit center and drive up the costs for patients, employers, and taxpayers.

159

159

PharmaVoice

MAY 5, 2025

The two obesity leaders are pulling on all levers to stay on top of the market.

Compounding 147

Compounding 147

STAT

MAY 6, 2025

Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China? As in many other industries, it’s so much cheaper to synthesize new compounds inside Chinese biotechnology firms once a novel biological target has been discovered in American laboratories.

Compounding 142

Compounding Pharmaceutical Companies Pharmaceutical Companies FDA 142

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

MAY 9, 2025

The new at-home test aims to increase comfort and screening timeliness through a more accessible method.

FDA 129

FDA 129

Pharmafile

MAY 6, 2025

Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofis consumer healthcare division, positioning Opella as a new independent leader in the global consumer health space. The deal brings Sanofi approximately 10bn in net cash proceeds. Sanofi retains a 48.2% share in Opella, with Bpifrance […] The post Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant appeared first on Pharmafile.

100

100

Pharmaceutical Technology

MAY 5, 2025

The US FDA has accepted Novo Nordisks new drug application (NDA) submission for the 25 mg oral formulation of Wegovy (semaglutide).

FDA 97

FDA 97

PharmaVoice

MAY 6, 2025

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

147

147

STAT

MAY 5, 2025

MILAN — For more than three decades, a charity here has funded research aimed at developing medicines for genetic diseases. Recently, though, it added an unusual new role — as a gene therapy company of sorts.  The charity, the Telethon Foundation, took ownership from a small biotech of a drug that has been approved in Europe to treat an ultra-rare immune disorder called ADA-SCID.

Immunization 135

Immunization 135

The Guardian - Pharmaceutical Industry

MAY 9, 2025

Providing semaglutide for all those eligible may bring productivity gains as people are able to work more Giving weight loss jabs to everyone eligible for them could boost the UK economy by 4.5bn, according to research. Worldwide, about 3.8 billion people over 25 and just under 750 million children and young people are forecast to be overweight or obese by 2050.

87

87

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Checkup by Singlecare

MAY 6, 2025

Zinc is an essential nutrient for many bodily processes, such as immune function and wound healing. Your body doesnt naturally produce it, so you must consume it in the foods you eat or take a supplement to avoid a zinc deficiency. Luckily, many foods you probably already eat are chock-full of zinc, including seafood, red meat, poultry, whole grains, and legumes.

Immunization 78

Immunization Mayo Clinic Dosage 78

Drug Topics

MAY 6, 2025

The use of electronic prescribing can also bridge the gap in clinical history, which can help pharmacists be aware of adverse drug reactions and medication interactions.

315

315

Pharmaceutical Technology

MAY 6, 2025

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

91

91

PharmaVoice

MAY 5, 2025

While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

100

100

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

MAY 6, 2025

WASHINGTON — Vinay Prasad, an academic and fierce critic of the medical mainstream, will be the next director of the Food and Drug Administration center that oversees the regulation of vaccines, gene therapies, and the blood supply.  Prasad, previously an epidemiology professor at the University of California, San Francisco, has sharply criticized the FDA in the past, including the Center for Biologics Evaluation and Research, the unit he will now lead.

Vaccines 145

Vaccines FDA 145

Pharmacy Times

MAY 6, 2025

Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.

80

80

Fierce Healthcare

MAY 9, 2025

Loss of services and support systems will result in the rollback of advancements made around human and civil rights for people with intellectual and developmental disabilities.

70

70

Drug Topics

MAY 9, 2025

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how its assisting with compliance.

281

281

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

PhRMA

MAY 1, 2025

Patients in the U.S. will soon be left with fewer new, affordable and convenient treatments, if Congress fails to fix a harmful provision in the Inflation Reduction Act (IRA) referred to as the “pill penalty.

179

179

European Pharmaceutical Review

MAY 5, 2025

New clinical findings show that Johnson & Johnsons monoclonal antibody Tremfya (guselkumab) enabled sustained clinical and endoscopic efficacy for ulcerative colitis patients at two years. This is based on the long-term extension study of the Phase III QUASAR trial , which evaluated adults with moderately-to-severely active forms of the disease.

FDA 64

FDA 64

STAT

MAY 9, 2025

WASHINGTON — U.S. regulators have approved the first  cervical cancer  testing kit that allows women to collect their own sample at home before shipping it to a laboratory, according to a medical device company. Teal Health said Friday the Food and Drug Administration approved its Teal Wand for home use, offering a new way to collect vaginal samples that can detect the HPV virus that causes cervical cancer.

FDA 118

FDA 118

Pharmacy Times

MAY 9, 2025

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

73

73

pharmaphorum

MAY 6, 2025

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients

71

71

Drug Topics

MAY 12, 2025

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

247

247

PhRMA

MAY 1, 2025

The 340B hospital markup program continues to skyrocket every year. Yet there is little to no evidence that this immense growth is benefiting the uninsured and low-income patients that the program was designed to serve. If the money isn’t going to help patients, where is it going?

Hospitals 179

Hospitals 179

Pharmafile

MAY 9, 2025

Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study of GAL-101, a novel therapy aimed to treat serious neurodegenerative eye and brain conditions. The SAD study showed that GAL-101 was well-tolerated and has a strong safety and pharmacokinetic profile. These promising results have allowed […] The post Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases appeared first on Ph

59

59

STAT

MAY 1, 2025

The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative: medetomidine. In the past year, the anesthetic has become an increasingly common element in the drug supply, with cities and states including Philadelphia, Pittsburgh, Chicago, and San Francisco reporting cases of medetomidine-involved overdoses.

128

128

Pharmacy Times

MAY 9, 2025

Student pharmacists can work toward a better future for patients, themselves, and the profession.

73

73

pharmaphorum

MAY 6, 2025

A potentially pivotal trial PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data

66

66

Drug Topics

MAY 9, 2025

Vin Gupta, MD, former Chief Medical Officer at Amazon Pharmacy and renowned US medical analyst, discusses pharmacists ability to reach communities and address social determinants of health.

247

247

The Checkup by Singlecare

MAY 12, 2025

MiraLax is a popular brand-name, over-the-counter (OTC) laxative that helps relieve constipation. Containing the active ingredient polyethylene glycol 3350 (PEG 3350), MiraLax is FDA approved to treat occasional constipation in adults. It has several off-label uses, too, including treating chronic constipation, constipation related to irritable bowel syndrome (IBS), bowel preparation for colonoscopy procedures, and treating constipation in children (which the American Academy of Pediatrics consi

Packaging 52

Packaging Labelling FDA 52

Fierce Healthcare

MAY 6, 2025

NEW ORLEANSIn the face of economic uncertainty, health system executives and venture capitalists are setting a high bar for digital health and artificial intelligence investments.

69

69

STAT

MAY 5, 2025

WASHINGTON — Hospitals, health centers, and patient advocates this week plan to escalate their pressure on federal lawmakers to oppose cuts to the Medicaid program. The groups are increasing their public calls to lawmakers, standing up new collaborations, and increasing investments in advertising to discourage lawmakers from cutting hundreds of billions of dollars in the program.

Hospitals 127

Hospitals Insurance 127